This study is being done to answer the following questions: 1. Is adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) better, the same as, or worse than the usual treatment alone for untreated older patients with CLL? 2. Can patients who have no detectable CLL after a year of receiving the usual treatment plus the new anti-cancer drug discontinue therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for chronic lymphocytic leukemia. The usual approach is defined as care most people get for chronic lymphocytic leukemia.
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia
OPEN TO ACCRUAL